For the first time in the history of the HIV epidemic, the world has a tool that could, in principle, drive new infections toward zero. It is not a vaccine. It is not a cure. It is an injection given twice a year, and in clinical trials it stopped HIV transmission completely.
Lenacapavir, sold under the brand name Yeztugo by Gilead Sciences, represents the most powerful form of pre-exposure prophylaxis ever developed. The PURPOSE 1 trial recorded zero incident infections among cisgender women who received the drug. The PURPOSE 2 trial demonstrated similarly high efficacy among cisgender men and gender-diverse people. The World Health Organization now recommends it. After decades of daily pills, condom campaigns, and behavioral interventions that achieved only partial control of the epidemic, a biomedical silver bullet has arrived.
But it has arrived into a world that may not be ready for it. The drug’s rollout has been marked not by scientific obstacles but by a cascade of political and economic failures. Funding has been slashed. Supply cannot meet demand. Licensing agreements exclude entire countries. Delivery logistics have been disrupted by armed conflict. And the nation that pledged to bring the drug to millions has done so slowly, while simultaneously demanding that recipient countries commit to severing their own lifelines.
What happens when a perfect scientific tool meets an imperfect world is not a story about science. It is a story about everything science cannot control.
The Breakthrough
Lenacapavir belongs to a class of drugs called capsid inhibitors. It works by interfering with the protein shell that protects HIV’s genetic material, disrupting multiple stages of the viral life cycle. Its key advantage over older PrEP options is duration. Daily oral pills require consistent adherence, and adherence has always been the weak link in HIV prevention. People forget. People run out of refills. People stop when side effects emerge, or when stigma makes daily pill-taking feel like a confession. A twice-yearly injection removes nearly all of those hurdles.
The efficacy data stunned the global health community. The PURPOSE 1 trial, conducted across sites in sub-Saharan Africa, found zero new HIV infections among women receiving lenacapavir. PURPOSE 2, which included cisgender men, transgender women, and gender-diverse people across multiple continents, reinforced the finding. The drug did not merely reduce risk. It eliminated it.
Gilead moved quickly to license the drug to six generic manufacturers, and the Clinton Health Access Initiative brokered a landmark deal with Dr. Reddy’s Laboratories that brought the per-person annual cost to approximately $40. The production cost itself is estimated at roughly $25 per person per year. For the first time in the epidemic’s history, the economics of HIV prevention aligned with the scale of the problem.
Then the politics caught up.
The Funding Gap
In April 2026, the United States pledged to provide lenacapavir PrEP to 3 million people over three years. It was a headline-grabbing commitment from the administration, one that acknowledged the drug’s transformative potential. But in practice, supplies have been slow to arrive at the facilities that need them. The gap between announcement and delivery has been wide enough that frontline clinicians in high-burden countries describe the rollout as badly faltering.
The broader context is a dramatic restructuring of the U.S. foreign aid apparatus. The Trump administration’s cuts to global health programs disrupted the very delivery infrastructure that makes PrEP distribution possible. Linda-Gail Bekker, director of the Desmond Tutu Health Foundation at the University of Cape Town, described the impact in stark terms, noting that the entire program architecture has been destabilized. Clinics that once received consistent support for HIV services now face uncertainty about whether they can maintain staffing, cold chains, and patient follow-up.
The Global Fund to Fight AIDS, Tuberculosis and Malaria has acknowledged a fundamental mismatch between demand and supply. Martin Auton, a senior official at the Global Fund, pointed out that while demand for lenacapavir is substantial and growing, the organization does not have the money to meet it. Somebody would have to pay for that additional demand, and at the moment there is no money available.
The MOU Condition
A further complication has emerged in the form of new conditions attached to U.S. aid. Recipient countries are now required to sign memoranda of understanding committing to wean themselves off American assistance by 2030. In theory, the goal of self-sufficiency is unobjectionable. In practice, the negotiations have been fraught.
Zambia provides a case in point. Talks with the U.S. government stalled over demands that extended well beyond health policy. According to reports, the U.S. side sought access to Zambian health data and made requests related to the country’s mineral rights. The linkage between HIV prevention aid and resource extraction represents a new and troubling dimension of global health diplomacy, one that threatens to delay the delivery of a lifesaving drug while countries negotiate terms that have little to do with public health.
The Exclusion Problem
Gilead’s licensing strategy, while generous in some respects, includes a critical gap. The company signed deals with generic manufacturers to produce lenacapavir for 120 low- and middle-income countries, primarily in sub-Saharan Africa and parts of Asia. But Brazil was excluded. So were many other so-called middle-income countries that face significant HIV burdens but whose GDP per capita places them above arbitrary licensing thresholds.
The result is a patchwork of access that mirrors the global inequalities HIV has always tracked. A person living in Malawi can potentially receive generic lenacapavir at the brokered price of $40 per year. A person living in Brazil cannot. And in the United States itself, where there is no generic competition, the projected market price for the drug exceeds $25,000 per person per year, roughly one thousand times the estimated production cost.
Mitchell Warren, executive director of the advocacy organization AVAC, characterized the situation as a historic mismatch between scientific possibility and political and economic reality. In his assessment of more than three decades working in the field, the greatest scientific opportunity the field has ever seen has been met by the most destructive political and economic conditions imaginable.
Logistics at the Edge of the World
Even when funding and political will align, the practical challenges of reaching patients with a twice-yearly injectable are substantial. The drug requires cold chain storage. It must be administered by trained health workers. Patients must be tracked and recalled for their next dose six months later, an interval that makes adherence monitoring easy in theory but difficult in practice for mobile populations.
And then there are the disruptions no one planned for. The war involving Iran has interrupted flight routes across parts of the Middle East and East Africa, causing what supply chain managers describe as hiccups in delivery schedules. When a drug requires injection every six months, even small delays can cascade into missed doses that reduce protection and increase the risk of breakthrough infections.
What the Bottleneck Reveals
The lenacapavir story is not fundamentally about a drug. It is about the limits of a purely biomedical approach to epidemic disease. The scientific community has done its job. It produced a molecule that prevents HIV infection with near-perfect reliability. It demonstrated efficacy across populations, genders, and continents. It brought the manufacturing cost down to a figure that should make universal access feasible.
But a molecule does not deliver itself. It does not negotiate trade agreements, weather funding cuts, survive bureaucratic restructuring, or find its way to a rural clinic in a country whose aid package has been held hostage over mineral rights. The gap between what science can achieve and what public health can deliver is not a scientific gap. It is a political one.
The HIV epidemic has killed more than 40 million people. It remains one of the deadliest infectious diseases in human history. For the first time, the world has a tool that could bring it under lasting control. The question is whether the world can organize itself well enough to use it.
References
Cohen, J. (2026, July 24). This drug could help end the HIV epidemic. Its rollout has hit speed bumps. Science.
Gilead Sciences. (2025). PURPOSE 1 trial results: Lenacapavir for PrEP in cisgender women. New England Journal of Medicine.
Gilead Sciences. (2026). PURPOSE 2 trial results: Lenacapavir for PrEP in cisgender men and gender-diverse people. The Lancet HIV.
AVAC. (2026). Global PrEP watch: Lenacapavir access and licensing update.
Clinton Health Access Initiative. (2026, March). Agreement with Dr. Reddy’s Laboratories for generic lenacapavir.
Unitaid. (2026). Market and access landscape for long-acting injectable PrEP.
World Health Organization. (2026). WHO recommends lenacapavir for HIV pre-exposure prophylaxis.
The Global Fund to Fight AIDS, Tuberculosis and Malaria. (2026). Supply and demand projections for long-acting PrEP.
WIRED. (2025, February). The next generation of HIV prevention is here. Can the world afford it?